IDEX Health & Science Announces Acquisition of New Microfluidics Company
News Dec 13, 2017
Credit: IDEX Health and Science
Located in Zweibrücken, Germany, thinXXS Microtechnology is a leader in the development and production of plastic microfluidic consumables serving the Life Sciences, Point of Care, and Veterinary markets. This acquisition will serve to establish IDEX Health & Science as the leader in microfluidic technologies, and sharpen its focus on the growth of integrated optofluidic sub-systems, components, and highly engineered solutions across its target markets.
Commenting on the acquisition, IDEX Health & Science President Gus Salem stated, “thinXXS is our second microfluidic asset acquisition that represents an incremental building block to our microfluidic technologies platform.” Salem continued, “The company’s market-leading technology and product portfolio are a fantastic fit with our microfluidics growth strategy by providing greater access to our core life science instrumentation market and creating new growth opportunities within the Point of Care, and Veterinary markets.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.
Like what you just read? You can find similar content on the communities below.Analysis & Separations Biopharma Cancer Research Cell Science Drug Discovery Genomics Research Proteomics & Metabolomics Immunology & Microbiology
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE